Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
NCT ID: NCT04924075
This clinical trial is studying a new treatment called belzutifan for patients with certain advanced tumors, including pheochromocytoma, paraganglioma, pancreatic neuroendocrine tumors, and other s...
Recruiting
Phase: PHASE2
Type: interventional
Locations: Toronto, Ontario, Canada, Saint Petersburg, Leningradskaya Oblast, Russian Federation +117 more
